Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1981 Jun;43(6):786–792. doi: 10.1038/bjc.1981.116

Value of serum calcitonin estimation in clinical oncology.

H Mulder, W H Hackeng, J Silberbusch, G J den Ottolander, C van der Meer
PMCID: PMC2010708  PMID: 7248159

Abstract

In 132 consecutive patients with carcinoma of various organs, a higher serum immunoreactive calcitonin (ICT) concentration (median level 50 pg/ml) was found than in 68 normal subjects (median level 20 pg/ml). The incidence of hypercalcitoninaemia was 40%. All 9 patients with primary liver-cell carcinoma were hypercalcitoninaemic. On the other hand, none of the 7 patients with a carcinoma of the breast had raised ICT levels. In bronchogenic cancer a relationship between ICT and cell type was found, with a predominance of high ICT in patients with oatcell and other undifferentiated types, whereas in squamous-cell carcinomas and adenocarcinomas of the lung hypercalcitoninaemia was relatively rare. When we divided all our patients according to differentiation of the tumour cell, it was found that the lower the degree of differentiation, the higher the ICT concentration, whereas opposite results were observed for CEA. When ICT and CEA were estimated concurrently, we found at least one marker increased in 70% of our patients. Our results demonstrate that patients with metastases in the liver have more frequently and increased ICT. In addition, we conclude that lifespan can be expected to be lower in patients with high ICT levels. In a longitudinal study of 46 patients, there was a positive correlation between change in serum ICT and tumour mass.

Full text

PDF
786

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi I., Abe K. [Ectopic calcitonin producing neoplasms]. Nihon Rinsho. 1976 Oct 10;34(10):2981–2986. [PubMed] [Google Scholar]
  2. BERKSON J., GAGE R. P. Calculation of survival rates for cancer. Proc Staff Meet Mayo Clin. 1950 May 24;25(11):270–286. [PubMed] [Google Scholar]
  3. Coombes R. C., Hillyard C., Greenberg P. B., MacIntyre I. Plasma-immunoreactive-calcitonin in patients with non-thyroid tumours. Lancet. 1974 Jun 1;1(7866):1080–1083. doi: 10.1016/s0140-6736(74)90557-1. [DOI] [PubMed] [Google Scholar]
  4. Dambacher M. A., Hunziker W., Fischer J. A. Die Bedeutung des Plasma-Calcitonins für die klinische Diagnostik. Dtsch Med Wochenschr. 1977 Aug 19;102(33):1191–1193. doi: 10.1055/s-0028-1106725. [DOI] [PubMed] [Google Scholar]
  5. GELLHORN A. Recent studies on pathophysiologic mechanisms in human neoplastic disease. J Chronic Dis. 1958 Jul;8(1):158–170. doi: 10.1016/0021-9681(58)90046-8. [DOI] [PubMed] [Google Scholar]
  6. Hackeng W. H., Schellekens A. P., Schopman W. A radioimmunoassay for human calcitonin. Horm Metab Res. 1970 Sep;2(5):310–311. [PubMed] [Google Scholar]
  7. Lamberts S. W., Hackeng W. H., Visser T. J. Dissociation and association between calcitonin and adrenocorticotropin secretion. J Clin Endocrinol Metab. 1980 Mar;50(3):565–568. doi: 10.1210/jcem-50-3-565. [DOI] [PubMed] [Google Scholar]
  8. McKenzie C. G., Evans I. M., Hillyard C. J., Hill P., Carter S., Tan M. K., MacIntyre I. Biochemical markers in bronchial carcinoma. Br J Cancer. 1977 Dec;36(6):700–707. doi: 10.1038/bjc.1977.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Milhaud G., Calmettes C., Coutris G., Moukhtar M. S. Thyrocalcitonin, a new chapter in human pathology. Isr J Med Sci. 1971 Mar;7(3):358–358. [PubMed] [Google Scholar]
  10. Mulder H., Hackeng W. H. Ectopic secretion of calcitonin. Acta Med Scand. 1978;204(4):253–256. doi: 10.1111/j.0954-6820.1978.tb08435.x. [DOI] [PubMed] [Google Scholar]
  11. Mulder H., Silberbusch J., Hackeng W. H., van der Meer C., den Ottolander G. J. Hypercalcitoninaemia in patients with chronic inflammatory disease. Neth J Med. 1980;23(3):129–131. [PubMed] [Google Scholar]
  12. Persijn J. P., Korsten C. B. The development of a radioimmuno-assay for carcino-embryonic antigen with some applications. Clinical evaluation of carcino-embryonic antigen, I. J Clin Chem Clin Biochem. 1976 Aug;14(8):377–387. doi: 10.1515/cclm.1976.14.1-12.377. [DOI] [PubMed] [Google Scholar]
  13. Silva O. L., Becker K. L., Primack A., Doppman J. L., Snider R. H. Increased serum calcitonin levels in bronchogenic cancer. Chest. 1976 Apr;69(4):495–499. doi: 10.1378/chest.69.4.495. [DOI] [PubMed] [Google Scholar]
  14. Silva O. L., Becker K. L., Primack A., Doppman J., Snider R. H. Ectopic production of calcitonin. Lancet. 1973 Aug 11;2(7824):317–317. doi: 10.1016/s0140-6736(73)90808-8. [DOI] [PubMed] [Google Scholar]
  15. Vaitukaitis J. L. Peptide hormones as tumor markers. Cancer. 1976 Jan;37(1 Suppl):567–572. doi: 10.1002/1097-0142(197601)37:1+<567::aid-cncr2820370722>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  16. Whitelaw A. G., Cohen S. L. Ectopic production of calcitonin. Lancet. 1973 Aug 25;2(7826):443–443. doi: 10.1016/s0140-6736(73)92300-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES